Pharma News

Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced it has signed an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, allowing Merck KGaA, Darmstadt, Germany to assess Quris’ BioAI safety prediction platform, comparing it to traditional in vitro and in vivo approaches.

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The target action date for the FDA decision on this investigational use is June 9, 2022.

IIHMR University, Jaipur on Wednesday inaugurated its 26th Pradanya Annual Global Conference on Innovations in Healthcare and Education: The Decade of Acceleration for Global Goals, a 3-day conference attended by 30 speakers from 25+ country and over 2000 delegates. Dr. P.R. Sodani, President, IIHMR University welcomed the guest, speakers, and delegates in the inaugural session and introduced the conference theme and tracks to the audience. Dr.

Global pharma major Lupin Limited announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application, Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vials to market a generic equivalent of Brovana ® Inhalation Solution, 15 mcg /2 ml of Sunovion Pharmaceuticals Inc. (Sunovion).

Scientists at McMaster University who have developed an inhaled form of COVID vaccine have confirmed it can provide broad, long-lasting protection against the original strain of SARS-CoV-2 and variants of concern.

The research, recently published in the journal Cell, reveals the immune mechanisms and significant benefits of vaccines being delivered directly into the respiratory tract, rather than by traditional injection.

The phase II trial, led by researchers at St George’s, University of London and St George’s Hospital was joint-funded by the US-based Alzheimer’s Drug Discovery Foundation and the UK Alzheimer’s Society. The trial tested whether tadalafil increases brain blood flow in older men and women with narrowing of the brain arteries, a condition that can cause strokes and vascular dementia.

Glenmark Pharmaceuticals Limited a global, innovation-driven pharmaceutical company and Canadian pharmaceutical company SaNOtize Research & Development Corp. today announced launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India; for the treatment of adult patients with COVID-19 who have high risk of progression of the disease. Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.

A team of scientists has developed a new technology, platform for fluorometric detection of pathogens such as viruses by measurement of fluorescent light emitted. The potential of the new technology has been demonstrated for the detection of SARS-CoV-2. This technology platform can also be used to detect other DNA/RNA pathogens such as HIV, influenza, HCV, Zika, Ebola, bacteria, and other mutating/evolving pathogens.

The National Health Authority (NHA) under its flagship scheme of Ayushman Bharat Digital Mission (ABDM) announced completion of 27 major integrations across Government and private sector. These integrations with organizations offering Health Management Information Systems (HMIS), Laboratory Management Information Systems (LMIS), health locker services, health tech services and other digital services are a step towards developing a user-inclusive, integrated and interoperable digital healthcare eco-system for the country.